Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magda Bahcall

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Medicinal Chemistry|November 17, 2015
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance MutationJohn M Hatcher, Magda Bahcall, Hwan Geun Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
European Journal of Medicinal Chemistry|May 22, 2017
Discovery of a potent dual ALK and EGFR T790M inhibitorJaebong Jang, Jung Beom Son, Ciric To, et al.
Journal of Medicinal Chemistry|April 18, 2018
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)Chelsea E Powell, Yang Gao, Li Tan, et al.
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Chemistry|November 17, 2015
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance MutationJohn M Hatcher, Magda Bahcall, Hwan Geun Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2025
Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2016
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung CancerCurtis R Chong, Magda Bahcall, Marzia Capelletti, et al.
European Journal of Medicinal Chemistry|May 22, 2017
Discovery of a potent dual ALK and EGFR T790M inhibitorJaebong Jang, Jung Beom Son, Ciric To, et al.
Journal of Medicinal Chemistry|April 18, 2018
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)Chelsea E Powell, Yang Gao, Li Tan, et al.
Nature|March 3, 2022
Silent mutations reveal therapeutic vulnerability in RAS Q61 cancersYoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, et al.
Cancer Research|June 7, 2015
Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2Junko Tanizaki, Dalia Ercan, Marzia Capelletti, et al.
Cancer Research|April 2, 2017
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 InhibitorsTakayuki Kosaka, Junko Tanizaki, Raymond M Paranal, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Molecular Cancer Therapeutics|November 18, 2021
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent ResistanceMagda Bahcall, Cloud P Paweletz, Yanan Kuang, et al.
Pageof 2